Antibody Drug Conjugates in HER2+ Breast Cancer

Objectives

- Review and discuss the development, clinical utility, and pharmacokinetic profiles of ADCs in HER2+ breast cancer
- Obtain feedback from subject matter experts on the safety and efficacy of antibody drug conjugates in HER2+ breast cancer
- Identify factors that influence treatment selection and planning for patients with HER2+ breast cancer
- Gain insight surrounding common tactics in the management of toxicities associated with ADCs